Innocuous Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 8 Year, 5 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth -50.80%
- Profit Growth 59.12%
- Ebitda 59.15%
- Net Worth -28.01%
- Total Assets 85.03%
About Innocuous Pharmaceuticals
Innocuous Pharmaceuticals Private Limited (IPPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 August 2016 (Eight years and five months 24 days old ). Its registered office is in Lucknow, Uttar Pradesh.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Shail Singh and Ritesh Singh serve as directors at the Company.
Company Details
- Location Lucknow, Uttar Pradesh
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U51909UP2016PTC085881
-
Company No.
085881
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
24 Aug 2016
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
What products or services does Innocuous Pharmaceuticals Private Limited offer?
Innocuous Pharmaceuticals Private Limited offers a wide range of products and services, including Vitamins & Supplements, Multivitamins.
Who are the key members and board of directors at Innocuous Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shail Singh
|
Director | 24-Aug-2016 | Current |
|
Ritesh Singh
|
Director | 17-Aug-2018 | Current |
Financial Performance of Innocuous Pharmaceuticals.
Innocuous Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 50.8% decrease. The company also saw a substantial improvement in profitability, with a 59.12% increase in profit. The company's net worth observed a substantial decline by a decrease of 28.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Innocuous Pharmaceuticals?
In 2017, Innocuous Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Innocuous Pharmaceuticals?
Unlock and access historical data on people associated with Innocuous Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Innocuous Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Innocuous Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
